| 59.95 -3.91 (-6.12%) | 06-02 10:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 89.56 |
1-year : | 102.9 |
| Resists | First : | 76.67 |
Second : | 88.09 |
| Pivot price | 68.22 |
|||
| Supports | First : | 58.2 |
Second : | 48.42 |
| MAs | MA(5) : | 63.56 |
MA(20) : | 71.83 |
| MA(100) : | 66.7  |
MA(250) : | 51.21 |
|
| MACD | MACD : | -5 |
Signal : | -3.9 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 8.1 |
| RSI | RSI(14): 22 |
|||
| 52-week | High : | 109 | Low : | 7.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed above bottom band by 1.1%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 65.3 - 65.93 | 65.93 - 66.3 |
| Low: | 61.67 - 62.49 | 62.49 - 62.98 |
| Close: | 62.92 - 64.25 | 64.25 - 65.06 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Mon, 01 Jun 2026
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Thu, 28 May 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - BioSpace
Wed, 27 May 2026
How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan
Tue, 12 May 2026
Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - Yahoo Finance
Thu, 07 May 2026
Nektar Therapeutics Reports First Quarter 2026 Financial Results - PR Newswire
Sat, 02 May 2026
How The Rezpegaldesleukin Story Is Recasting The Narrative For Nektar Therapeutics (NKTR) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 79.9 (%) |
| Shares Short | 4,370 (K) |
| Shares Short P.Month | 3,630 (K) |
| EPS | -7.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.29 |
| Profit Margin | -284.2 % |
| Operating Margin | -352.3 % |
| Return on Assets (ttm) | -15.3 % |
| Return on Equity (ttm) | -53.6 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 1.64 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | -3.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.4 |
| PEG Ratio | 0.3 |
| Price to Book value | 2.51 |
| Price to Sales | 35.63 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|